1 Abstract
Vaccination was a key intervention in controlling the COVID-19 pandemic globally. In early 2021, Norway faced significant regional variations in COVID-19 incidence and prevalence, with large differences in population density, necessitating efficient vaccine allocation to reduce infections and severe outcomes. This study explored alternative vaccination strategies to minimize health outcomes (infections, hospitalizations, ICU admissions, deaths) by varying regions prioritized, extra doses prioritized, and implementation start time.
Using two models (individual-based and meta-population), we simulated COVID-19 transmission during the primary vaccination period in Norway, covering the first 7 months of 2021. We investigated alternative strategies to allocate more vaccine doses to regions with a higher force of infection. We also examined the robustness of our results and highlighted potential structural differences between the two models.
Our findings suggest that early vaccine prioritization could reduce COVID-19 related health outcomes by 8% to 20% compared to a baseline strategy without geographic prioritization. For minimizing infections, hospitalizations, or ICU admissions, the best strategy was to initially allocate all available vaccine doses to fewer high-risk municipalities, comprising approximately one-fourth of the population. For minimizing deaths, a moderate level of geographic prioritization, with approximately one-third of the population receiving doubled doses, gave the best outcomes by balancing the trade-off between vaccinating younger people in high-risk areas and older people in low-risk areas.
The actual strategy implemented in Norway was a two-step moderate level aimed at maintaining the balance and ensuring ethical considerations and public trust. However, it did not offer significant advantages over the baseline strategy without geographic prioritization. Earlier implementation of geographic prioritization could have more effectively addressed the main wave of infections, substantially reducing the national burden of the pandemic.
Author summary We utilized two geographic-age-structured models (an individual-based model and a meta-population model) to conduct a scenario-based analysis aimed at evaluating strategies for geographic prioritization of COVID-19 vaccines in Norway. By reconstructing the dynamics of COVID-19 transmission from January to July of 2021, we compared various alternative vaccination strategies through model simulations, given the limited number of vaccine doses. We found that prioritization of vaccines based on geographic location, alongside considering age, was preferable to a baseline strategy without geographic prioritization. We assessed the selection of which municipalities to prioritize and the degree of prioritization they should receive. Our findings indicated that optimal strategies depended on whether the aim was to minimize infections, hospitalizations, ICU admissions, or deaths. Trade-offs in infection growth between municipalities and subsequent risk-class allocations (such as age groups) were the primary factors influencing optimal vaccine allocation. Furthermore, we found that earlier implementation of most geographic prioritization strategies was advantageous in reducing the overall burden of COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Research Council of Norway under grant number 312721 for the research initiative titled “COVID-19 in Norway: A Real-Time Analytical Pipeline for Preparedness, Planning, and Response during the COVID-19 Pandemic in Norway.”.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Norwegian health data used in this study is sourced from the Emergency Preparedness Register for COVID-19 (Beredt C19). The right to access one's own personal data in health registries follows from the Health Registry Act 24 and from GDPR chapter III, art. 15 (with certain exceptions in the Personal Data Act 16 and 17). Ethics approval has been obtained for the use of data in this article, authorized through the Norwegian Health Preparedness Act, paragraphs 2-4. More information regarding this approval can be found at https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The aggregated case data and computational code for two models are accessible to the public and shared on GitHub, available at https://github.com/folkehelseinstituttet/COVID19_vaccination-IBM or https://github.com/imlouischan/corona-no, and https://github.com/folkehelseinstituttet/COVID19_vaccination-MPM or https://github.com/Gulfa/regional_vaccination. However, due to privacy considerations, vaccination data is not accessible to the public. Instead, demonstration of pseudo data with added noise on the original data is used. The mobility data was collected and provided by Telenor Norway. Requests for access to mobility data should be directed to Telenor Research via email: TelenorResearch{at}telenor.com.
https://github.com/folkehelseinstituttet/COVID19_vaccination-IBM
https://github.com/imlouischan/corona-no
https://github.com/folkehelseinstituttet/COVID19_vaccination-MPM
